Division of Translational Medicine and Human Genetics

Projects

Impact of Pharmacogenetic Variants in the University of Pennsylvania Health System. The goal of this project is to identify actionable pharmacogenetics variants within the Penn Biobank and develop methods to identify drug-related outcomes in the electronic health record. Principal Investigators: Sony Tuteja, PharmD, MS

Dr. Sony Tuteja’s Precision Medicine Accelerator Fund Project

 

 

Clinical Implementation of CYP2C19 testing. The goals of this project are to establish CYP2C19 as a clinical test, initiate and create clinical decision support tools within the electronic health record, create a workflow for pharmacogenetic test billing and assess economic impact, and assess the need for provider and patient education. CYP2C19-Clopidogrel testing information. Investigators: Sony Tuteja, PharmD, MS and Jay Giri, MD, MPH

Assessment of prospective CYP2C19 genotype guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention (the ADAPT Study). The purpose of this study is to determine the clinical impact of CYP2C19 genotyping following percutaneous coronary intervention (PCI). Clinical trials.gov registration: NCT02508116 – Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention (ADAPT). Investigators: Sony Tuteja, PharmD, MS and Jay Giri, MD, MPH

 

Please contact Sony Tuteja, PharmD, MS if you are interested in collaborating on pharmacogenomics research projects sonyt@pennmedicine.upenn.edu

Share This Page: